Grace Financial Statements From 2010 to 2026

GRCE Stock   3.69  0.11  2.89%   
Grace Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Grace Therapeutics' valuation are provided below:
Market Capitalization
57.7 M
Earnings Share
(0.53)
There are over one hundred nineteen available fundamental trends for Grace Therapeutics, which can be analyzed over time and compared to other ratios. Investors should ensure to confirm all of Grace Therapeutics' regular performance against the performance from 2010 to 2026 to make sure the company is sustainable down the road. The current year's Market Cap is expected to grow to about 26 M. The current year's Enterprise Value is expected to grow to about 6.6 M

Grace Therapeutics Total Revenue

0.0

Check Grace Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Grace Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 6 K, Interest Expense of 318.8 K or Other Operating Expenses of 17 M, as well as many indicators such as Price To Sales Ratio of 35.86, Dividend Yield of 0.0 or PTB Ratio of 0.39. Grace financial statements analysis is a perfect complement when working with Grace Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Grace Stock
Check out the analysis of Grace Therapeutics Correlation against competitors.
For information on how to trade Grace Stock refer to our How to Trade Grace Stock guide.

Grace Therapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets46.4 M82.8 M45.2 M
Slightly volatile
Other Current Liabilities2.1 M1.2 M2.4 M
Very volatile
Total Current Liabilities2.9 M1.7 M3.5 M
Very volatile
Total Stockholder Equity80.4 M76.6 M38.7 M
Slightly volatile
Property Plant And Equipment Net16.4 K17.2 K585.4 K
Very volatile
Cash14.6 M25.5 M14.4 M
Slightly volatile
Non Current Assets Total59.5 M56.7 M26.5 M
Slightly volatile
Non Currrent Assets Other12.8 K13.5 K760.5 K
Slightly volatile
Cash And Short Term Investments20.7 M25.5 M19.5 M
Slightly volatile
Net Receivables107.7 K113.4 K602.2 K
Slightly volatile
Common Stock Shares Outstanding14.6 M13.9 MM
Slightly volatile
Liabilities And Stockholders Equity46.4 M82.8 M45.2 M
Slightly volatile
Total Liabilities9.6 M6.2 MM
Slightly volatile
Total Current Assets22.1 M26.1 M20.8 M
Slightly volatile
Inventory0.860.966.2 K
Slightly volatile
Accounts Payable1.3 M691.1 K1.2 M
Pretty Stable
Intangible Assets24.5 M47.3 M24.9 M
Slightly volatile
Common Stock1.1 K1.1 K92.5 M
Slightly volatile
Non Current Liabilities Total7.6 MM7.3 M
Very volatile
Short and Long Term Debt Total483 K436.5 K838.2 K
Slightly volatile
Short Term Debt64.1 K67.5 K761.6 K
Slightly volatile
Net Invested Capital57.6 M59.9 M60.8 M
Slightly volatile
Property Plant And Equipment Gross22.2 K23.4 K231 K
Slightly volatile
Capital Stock855900173.3 M
Slightly volatile
Net Working Capital27.5 M18.7 M48.6 M
Slightly volatile

Grace Therapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And AmortizationK6.3 K973.5 K
Slightly volatile
Interest Expense318.8 K303.6 K182.2 K
Slightly volatile
Other Operating Expenses17 M19.2 M16.5 M
Slightly volatile
Research Development8.7 M10.9 M8.7 M
Slightly volatile
Total Operating Expenses17 M19.2 M16.4 M
Slightly volatile
Selling General Administrative5.4 M8.2 MM
Slightly volatile
Selling And Marketing Expenses165.9 K174.6 K560.4 K
Pretty Stable
Interest Income451.4 K817.6 K258.3 K
Slightly volatile

Grace Therapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow13.4 M26.5 M13.5 M
Slightly volatile
End Period Cash Flow14.6 M25.5 M14.4 M
Slightly volatile
Stock Based Compensation992.2 K657 K1.2 M
Pretty Stable

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio35.8634.1527.1375
Slightly volatile
PTB Ratio0.390.370.2155
Slightly volatile
Days Sales Outstanding1.1 K1.1 K1.4 K
Slightly volatile
Book Value Per Share6.026.3442.5191
Slightly volatile
Stock Based Compensation To Revenue6.546.895.8721
Slightly volatile
Capex To Depreciation0.30.160.2444
Slightly volatile
PB Ratio0.390.370.2155
Slightly volatile
Inventory Turnover0.00720.00760.5527
Slightly volatile
Days Of Inventory On Hand52 K49.6 K31.4 K
Slightly volatile
Payables Turnover0.01190.01260.5415
Slightly volatile
Sales General And Administrative To Revenue18.825.3124.4745
Slightly volatile
Average Inventory349.8 K259.9 K267.7 K
Slightly volatile
Research And Ddevelopement To Revenue23.2624.4832.2031
Pretty Stable
Capex To Revenue0.30.320.8943
Pretty Stable
Cash Per Share2.02.1123.7268
Slightly volatile
Days Payables Outstanding40.3 K38.4 K12.9 K
Slightly volatile
Income Quality0.891.41.0785
Very volatile
Intangibles To Total Assets0.380.620.4988
Pretty Stable
Net Debt To EBITDA0.791.190.9951
Slightly volatile
Current Ratio7.910.599.5682
Pretty Stable
Receivables Turnover0.250.330.3854
Slightly volatile
Shareholders Equity Per Share6.026.3442.5191
Slightly volatile
Debt To Equity0.00780.00820.1026
Slightly volatile
Capex Per Share0.00320.00340.388
Slightly volatile
Average Receivables629 K799.5 K846.7 K
Very volatile
Revenue Per Share0.08670.09120.833
Slightly volatile
Interest Debt Per Share0.05580.05870.6281
Very volatile
Debt To Assets0.00670.0070.0377
Slightly volatile
Operating Cycle1.1 K1.1 K1.4 K
Slightly volatile
Price Book Value Ratio0.390.370.2155
Slightly volatile
Days Of Payables Outstanding40.3 K38.4 K12.9 K
Slightly volatile
Ebt Per Ebit0.740.690.915
Very volatile
Effective Tax Rate0.120.230.097
Slightly volatile
Company Equity Multiplier1.731.241.6266
Pretty Stable
Long Term Debt To Capitalization0.130.150.1611
Slightly volatile
Total Debt To Capitalization0.00770.00810.0867
Slightly volatile
Debt Equity Ratio0.00780.00820.1026
Slightly volatile
Quick Ratio7.8510.599.5383
Slightly volatile
Net Income Per E B T0.970.860.9245
Slightly volatile
Cash Ratio10.8410.326.2791
Slightly volatile
Days Of Inventory Outstanding52 K49.6 K31.4 K
Slightly volatile
Days Of Sales Outstanding1.1 K1.1 K1.4 K
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.121.151.0334
Slightly volatile
Price To Book Ratio0.390.370.2155
Slightly volatile
Fixed Asset Turnover2.492.626.9629
Slightly volatile
Debt Ratio0.00670.0070.0377
Slightly volatile
Price Sales Ratio35.8634.1527.1375
Slightly volatile
Asset Turnover0.00340.00360.0104
Slightly volatile
Price Fair Value0.390.370.2155
Slightly volatile

Grace Therapeutics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap26 M24.8 M11 M
Slightly volatile

Grace Fundamental Market Drivers

About Grace Therapeutics Financial Statements

Grace Therapeutics stakeholders use historical fundamental indicators, such as Grace Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Grace Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Grace Therapeutics' assets and liabilities are reflected in the revenues and expenses on Grace Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Grace Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Cost Of Revenue6.3 KK
Stock Based Compensation To Revenue 6.89  6.54 
Sales General And Administrative To Revenue 25.31  18.80 
Research And Ddevelopement To Revenue 24.48  23.26 
Capex To Revenue 0.32  0.30 
Revenue Per Share 0.09  0.09 
Ebit Per Revenue(75.39)(79.16)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Grace Therapeutics is a strong investment it is important to analyze Grace Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Grace Therapeutics' future performance. For an informed investment choice regarding Grace Stock, refer to the following important reports:
Check out the analysis of Grace Therapeutics Correlation against competitors.
For information on how to trade Grace Stock refer to our How to Trade Grace Stock guide.
You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Grace Therapeutics. If investors know Grace will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Grace Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.53)
Return On Assets
(0.12)
Return On Equity
(0.13)
The market value of Grace Therapeutics is measured differently than its book value, which is the value of Grace that is recorded on the company's balance sheet. Investors also form their own opinion of Grace Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Grace Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Grace Therapeutics' market value can be influenced by many factors that don't directly affect Grace Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Grace Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Grace Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Grace Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.